Efficacy of Levetiracetam in Pendular Nystagmus: A Randomized, Double-blind, Placebo-controlled trial with crossover - Levetiracetam in Pendular Nystagmus

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-000798-71-GB

Enrollment

Registered

2005-02-10

Start date

2004-08-11

Completion date

Unknown

Last updated

2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pendular Nystagmus from various etiology

Interventions

Trade Name: Keppra Product Name: Levetiracetam Product Code: EU/1/00/146/010 Pharmaceutical Form: Tablet Pharmaceutical form of the placebo: Tablet Route of administration of the placebo: Oral use

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Adult patients age 18-65 years 2. Presence of pendular nystagmus in primary gaze 3. Presence of symptoms of oscillopsia 4. Visual Acuity more than 6/60 at least in one eye Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: 1. Known allergy to Levetiracetam 2. Pregnancy 3. Breast feeding 4. Severe Renal Impairment 5. Currently taking Levetiracetam

Design outcomes

Primary

Measure	Time frame
Main Objective: To investigate the efficacy of Levetiracetam in reducing the degree of pendular nystagmus and oscillopsia (symptoms that the patients experience from nystagmus; illusion of movement of the seen world). ;Secondary Objective: ;Primary end point(s): 1. Reduction of degree of nystagmus, observed by eye movement recording 2. Resolution of symptoms of oscillopsia	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026